ICCM

IceCure Medical is a medical device company developing minimally invasive cryoablation technology for the treatment of tumors. The company's ProSense system uses liquid nitrogen-based cryoablation to freeze and destroy tumors, with initial focus on breast cancer and other solid tumors. IceCure's technology is designed to provide a less invasive alternative to surgical tumor removal, potentially offering advantages in cosmetic outcomes, recovery time, and treatment costs. The company has received regulatory clearances in Europe and is pursuing FDA approval for its technology in the United States.